Flatiron Blog Informing global evidence strategies with real-world data across multiple geographies Published on January 29, 2026 By Arun Sujenthiran, MD SharePosted inReal-World EvidenceRegulatoryHTA and Market AccessLife sciencesReal-World Data More to exploreFlatiron Health at ASH: Real-world evidence that reveals the why behind hematology treatment decisionsReal-World EvidenceHematologic malignanciesLife sciencesReal-World DataCrossing borders with real-world evidence: lessons from the elacestrant caseReal-World EvidenceCase studyBreast cancerHTA and Market AccessLife sciencesHEOR / RWEReal-World DataExternal control arms for emerging biopharma: building credible comparative evidenceReal-World EvidenceTrial designRegulatoryReal-World DataClinical development
Flatiron Health at ASH: Real-world evidence that reveals the why behind hematology treatment decisionsReal-World EvidenceHematologic malignanciesLife sciencesReal-World Data
Crossing borders with real-world evidence: lessons from the elacestrant caseReal-World EvidenceCase studyBreast cancerHTA and Market AccessLife sciencesHEOR / RWEReal-World Data
External control arms for emerging biopharma: building credible comparative evidenceReal-World EvidenceTrial designRegulatoryReal-World DataClinical development
